Results 51 to 60 of about 148,724 (217)
Selective ligands of the CB2 receptor are receiving considerable attention due to their potential as therapeutic agents for a variety of diseases. Recently, 7-hydroxy-5-oxopyrazolo[4,3-b]pyridine-6-carboxamide derivatives were shown to act at the CB2 ...
Claudia Mugnaini +15 more
doaj +1 more source
Abstract Background and aims Cannabis edible products are increasingly being sold on the illicit market around the world. Use of these products, typically labelled as containing Δ‐9‐tetrahydrocannabinol (THC), has been linked to adverse health effects, particularly amongst adolescents.
Matthew Gardner +9 more
wiley +1 more source
An exploratory chemical effort has been undertaken to develop a novel series of compounds as selective CB1 agonists. It is hoped that compounds of this type will have clinical utility in pain control, and cerebral ischaemia following stroke or traumatic ...
Robinson, Michael +16 more
core +1 more source
1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. [PDF]
New 1-benzhydryl-3-phenylurea derivatives and their 1-benzhydryl-3-phenylthiourea isosteres were synthesized and evaluated for their human CB1 and CB2 cannabinoid receptor affinity. These compounds proved to be selective CB1 cannabinoid receptor ligands,
Wouters, Johan +9 more
core +1 more source
Allosteric modulators restore orthosteric agonist binding to mutated CB1 receptors
Abstract Objectives To determine if diminished orthosteric agonist binding due to mutations in extracellular loops 1 or 2 of the cannabinoid receptor 1 (CB1) can be overcome by an allosteric modulator and restore agonist binding. Methods
Rachel Dopart, Debra A Kendall
openaire +3 more sources
Behavioral effects of the novel potent cannabinoid CB1 agonist AM 4054 [PDF]
Due to the ubiquity of the CB1 cannabinoid receptor throughout the nervous system, as well as the many potential therapeutic uses of CB1 agonist-based interventions, it is desirable to synthesize novel probes of the CB1 receptor. Here, the acute behavioral effects of systemic (i.p.) administration of the putative novel CB1 full agonist AM 4054 were ...
Peter J, McLaughlin +8 more
openaire +2 more sources
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Endocannabinoids, acting primarily through CB1 receptors, are critical modulators of neuronal activity, influencing cognitive functions and emotional processing.
Giota Tsotsokou +5 more
doaj +1 more source
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade +7 more
wiley +1 more source

